Mazdutide: What It Is and How It's Used in the Philippines
Mazdutide reference for Filipino peptide users. GLP-1 + Glucagon dual agonist from Innovent Biologics. China-developed, emerging PH availability.
Mazdutide: What It Is and How It's Used in the Philippines
Quick read: Mazdutide is a GLP-1 + Glucagon dual agonist developed by Innovent Biologics (China). Dosed at 3-6mg weekly, it's similar to retatrutide's mechanism but less studied. In PH, it's an emerging alternative to Western GLP-1 agonists, with limited community data.
What it is
Mazdutide activates GLP-1 (appetite suppression, insulin release) and glucagon (fat oxidation, energy expenditure) receptors. It's structurally similar to retatrutide's triple-agonist approach but without GIP.
Research from Chinese trials shows 10-15% weight loss over 24 weeks at 3-6mg weekly doses.
In the PH peptide community, mazdutide is emerging as a China-sourced alternative to retatrutide or tirzepatide, though availability and data are limited.
What it's used for
Primary use: Weight loss via dual GLP-1/Glucagon pathway.
Realistic expectations: 10-15% weight loss over 24 weeks based on trials.
Typical protocols
Standard protocol (from trials):
- Dose: 3-6mg subcutaneous weekly
- Titration: Start 3mg, increase to 6mg over weeks
- Duration: 6-12 months
What users typically report
Limited PH community data. Expected effects similar to other GLP-1 agonists: appetite suppression, gradual fat loss.
Common side effects
Expected: nausea, GI upset, constipation (similar to other GLP-1s).
Side effect management
Same as GLP-1 agonists: small frequent meals, avoid high-fat foods, manage nausea with famotidine.
Who this compound is for
Users interested in China-developed alternatives to Western GLP-1 agonists.
Who this compound is NOT for
Pregnancy/breastfeeding.
Gastroparesis.
PH-specific considerations
China-developed alternative, emerging: Limited PH availability. Most users stick to retatrutide, tirzepatide, or semaglutide.
Common stacks
Typically run standalone.
Things to watch
Same as GLP-1 agonists: fasting glucose, HbA1c, lipids.
Coming off / cycling
Appetite returns after stopping.
Related compounds
- Retatrutide — Triple agonist, Western-developed
- Tirzepatide — Dual GLP-1/GIP agonist
- Semaglutide — Pure GLP-1 agonist
Sources
- Bao 2023 — Mazdutide Phase 2 trial data
- Ji 2024 — GLP-1/Glucagon dual agonism mechanisms
Last updated: 2026-05-20. This page is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.